Cannabidiol, a compound found in cannabidiol (CBD), the active ingredient in marijuana, has been shown to ease symptoms in people with Alzheimer's disease and Tourette's syndromeand now it's being tested on children with autism.
SciSparc Ltd., an Israeli pharmaceutical company, says it has enrolled the first child in a clinical trial testing its cannabidiol-CannAmide-Palmitoylethanolamide combination for the treatment of symptoms of autism spectrum disorder (ASD) between the ages of 5 and 18, per a press release.
"The enrollment of our first patient means that we are moving towards a new frontier in the treatment of ASD," says SciSparc CEO Oz Adler.
"We are pleased to enroll the first patient in the trial, which will further our understanding of the potential role of SCI-210 in the treatment of ASD symptoms."
The randomized, double-blind, and placebo-controlled trial is being conducted at the National Autism Research Center in Israel, with 60 children between the ages of 5 and 18 taking either SCI-210 or a placebo for 20 weeks, reports the Wall Street Journal.
The Journal notes that there are currently no FDA-approved treatments for ASD, which affects one in 36 children
A customized collection of grant news from foundations and the federal government from around the Web.
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.